FR23C1036I1 - Anticorps qui se lient à il-23 - Google Patents

Anticorps qui se lient à il-23

Info

Publication number: FR23C1036I1
Authority: FR; France
Prior art keywords: antibodies; bind
Prior art date: 2013-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1036C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-08

Filing date

2023-10-13

Publication date

2023-12-08

2023-10-13 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2023-12-08 Publication of FR23C1036I1 publication Critical patent/FR23C1036I1/fr

2024-10-04 Application granted granted Critical

2024-10-04 Publication of FR23C1036I2 publication Critical patent/FR23C1036I2/fr

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Transplantation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

FR23C1036C 2013-03-08 2023-10-13 Anticorps qui se lient à il-23 Active FR23C1036I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361774732P	2013-03-08	2013-03-08
PCT/US2014/020064 WO2014137962A1 (fr)	2013-03-08	2014-03-04	Anticorps qui se lient à il-23

Publications (2)

Publication Number	Publication Date
FR23C1036I1 true FR23C1036I1 (fr)	2023-12-08
FR23C1036I2 FR23C1036I2 (fr)	2024-10-04

Family

ID=51488096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1036C Active FR23C1036I2 (fr)	2013-03-08	2023-10-13	Anticorps qui se lient à il-23

Country Status (40)

Country	Link
US (3)	US9023358B2 (fr)
EP (3)	EP2964258B1 (fr)
JP (1)	JP6096938B2 (fr)
KR (2)	KR20170103037A (fr)
CN (1)	CN105307681B (fr)
AP (1)	AP2015008708A0 (fr)
AR (1)	AR094877A1 (fr)
AU (1)	AU2014226094C1 (fr)
BR (1)	BR112015019611B1 (fr)
CA (1)	CA2901462C (fr)
CL (1)	CL2015002388A1 (fr)
CY (2)	CY1123589T1 (fr)
DK (1)	DK2964258T3 (fr)
EA (1)	EA031524B1 (fr)
EC (1)	ECSP15038626A (fr)
ES (1)	ES2822662T3 (fr)
FI (1)	FIC20230030I1 (fr)
FR (1)	FR23C1036I2 (fr)
HR (1)	HRP20201633T1 (fr)
HU (2)	HUE051357T2 (fr)
IL (2)	IL240731B (fr)
JO (1)	JOP20140049B1 (fr)
LT (2)	LT2964258T (fr)
MA (1)	MA38382A1 (fr)
MX (1)	MX370396B (fr)
MY (1)	MY171226A (fr)
NL (1)	NL301247I2 (fr)
NO (1)	NO2023037I1 (fr)
PE (1)	PE20151529A1 (fr)
PH (1)	PH12015501994B1 (fr)
PL (1)	PL2964258T3 (fr)
PT (1)	PT2964258T (fr)
RS (1)	RS60928B1 (fr)
SG (1)	SG11201507176VA (fr)
SI (1)	SI2964258T1 (fr)
TN (1)	TN2015000348A1 (fr)
TW (1)	TWI636063B (fr)
UA (1)	UA123198C2 (fr)
WO (1)	WO2014137962A1 (fr)
ZA (1)	ZA201505285B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR102417A1 (es) *	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
US20180291093A1 (en) *	2015-10-30	2018-10-11	Eli Lilly And Company	Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
AR111845A1 (es)	2017-05-03	2019-08-28	Lilly Co Eli	Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos
TWI744617B (zh)	2018-03-30	2021-11-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
TWI725532B (zh)	2018-09-11	2021-04-21	美商美國禮來大藥廠	治療牛皮癬之方法
TWI850365B (zh)	2019-04-22	2024-08-01	美商美國禮來大藥廠	治療克隆氏症(crohn's disease)的方法
KR20220054689A (ko)	2019-10-15	2022-05-03	일라이 릴리 앤드 캄파니	재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
CA3164996A1 (fr)	2019-12-20	2021-06-14	Novarock Biotherapeutics, Ltd.	Anticorps anti-interleukine-23 p19 et leurs methodes d'utilisation
CN112807428B (zh) *	2020-06-12	2024-08-27	江苏荃信生物医药股份有限公司	包含抗人白介素23单克隆抗体的药物组合物
WO2022041390A1 (fr) *	2020-08-28	2022-03-03	江苏荃信生物医药股份有限公司	Formulation liquide à faible viscosité comprenant un anticorps monoclonal anti-interleukine 23 humaine à concentration élevée, et son procédé de préparation
AR123477A1 (es)	2020-09-10	2022-12-07	Lilly Co Eli	Formulaciones de anticuerpos terapéuticos
US20240254217A1 (en)	2021-05-28	2024-08-01	Eli Lilly And Company	Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
CN113698480B (zh) *	2021-09-18	2022-07-01	东大生物技术(苏州)有限公司	一组il-23单克隆抗体及其医药用途
US20240391994A1 (en)	2021-09-30	2024-11-28	Eli Lilly And Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
WO2024077113A1 (fr)	2022-10-06	2024-04-11	Eli Lilly And Company	Méthodes de traitement de la fatigue liée à la colite ulcéreuse
CN120882881A (zh)	2023-02-22	2025-10-31	伊莱利利公司	溃疡性结肠炎的基因调控及其用途
AU2024236477A1 (en)	2023-03-10	2025-09-11	Eli Lilly And Company	Methods of treating ulcerative colitis
WO2025083549A1 (fr)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes
WO2025117506A1 (fr)	2023-11-29	2025-06-05	Gilead Sciences, Inc.	Traitement des maladies inflammatoires chroniques de l'intestin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
US7282204B2 (en)	2003-03-10	2007-10-16	Schering Corporation	Uses of IL-23 agonists and antagonists; related reagents
US8003108B2 (en) *	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
SI2452694T1 (sl)	2005-06-30	2019-05-31	Janssen Biotech, Inc.	Protitelesa proti-IL-23, sestavki in postopki uporabe
CN101248088A (zh) *	2005-08-25	2008-08-20	伊莱利利公司	抗il-23抗体
DK1937721T3 (da) *	2005-08-25	2010-10-18	Lilly Co Eli	Anti-IL-23 antistoffer
LT1931710T (lt) *	2005-08-31	2017-03-27	Merck Sharp & Dohme Corp.	Rekombinantiniai anti-il-23 antikūnai
LT2548577T (lt) *	2005-12-29	2017-04-10	Janssen Biotech, Inc.	Žmogaus anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
MX2009009080A (es) *	2007-02-23	2009-11-02	Schering Corp	Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
LT2426144T (lt)	2007-02-23	2018-12-10	Merck Sharp & Dohme Corp.	Genų inžinerijos būdu pagaminti anti-il-23p19 antikūnai
SI2131860T1 (sl) *	2007-03-20	2014-02-28	Eli Lilly And Company	Protitelesa proti sklerostinu
WO2008141044A2 (fr)	2007-05-08	2008-11-20	Genentech, Inc.	Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
WO2009082624A2 (fr) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci
EP2435480A1 (fr) *	2009-05-27	2012-04-04	Ablynx N.V.	Produits de construction protéiques biparatopiques dirigés contre il-23
ES2593754T3 (es) *	2010-11-04	2016-12-13	Boehringer Ingelheim International Gmbh	Anticuerpos anti-IL-23
CA2833212C (fr) *	2011-05-12	2020-06-09	Genentech, Inc.	Reaction multiple de surveillance du procede lc-ms/ms pour detecter les anticorps therapeutiques dans les echantillons d'animaux par des peptides de signature du cadre

2014
- 2014-02-25 AR ARP140100582A patent/AR094877A1/es active IP Right Grant
- 2014-02-25 TW TW103106335A patent/TWI636063B/zh active
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/ar active
- 2014-03-04 EA EA201591368A patent/EA031524B1/ru not_active IP Right Cessation
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/ko not_active Ceased
- 2014-03-04 MA MA38382A patent/MA38382A1/fr unknown
- 2014-03-04 PL PL14761062T patent/PL2964258T3/pl unknown
- 2014-03-04 MX MX2015011959A patent/MX370396B/es active IP Right Grant
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/fr active Active
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/ja active Active
- 2014-03-04 RS RS20201236A patent/RS60928B1/sr unknown
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/xx unknown
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/da active
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/fr not_active Withdrawn
- 2014-03-04 PT PT147610620T patent/PT2964258T/pt unknown
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/ko active Active
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/fr not_active Ceased
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/lt unknown
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/zh active Active
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
- 2014-03-04 HR HRP20201633TT patent/HRP20201633T1/hr unknown
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/hu unknown
- 2014-03-04 SI SI201431653T patent/SI2964258T1/sl unknown
- 2014-03-04 CA CA2901462A patent/CA2901462C/fr active Active
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/pt active IP Right Grant
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/fr active Pending
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 ES ES14761062T patent/ES2822662T3/es active Active
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/es active IP Right Grant
- 2014-03-04 UA UAA201508670A patent/UA123198C2/uk unknown
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/es unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/es unknown
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/el unknown
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/fi unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/no unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/nl unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/el unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/fr active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/hu unknown
- 2023-10-23 LT LTPA2023530C patent/LTC2964258I2/lt unknown

Also Published As

Publication number	Publication date
EP4311558A3 (fr)	2024-04-10
PE20151529A1 (es)	2015-10-28
PH12015501994B1 (en)	2023-03-01
JP6096938B2 (ja)	2017-03-15
HRP20201633T1 (hr)	2020-12-25
MA38382A1 (fr)	2017-11-30
PH12015501994A1 (en)	2016-01-11
AU2014226094B2 (en)	2016-06-23
TWI636063B (zh)	2018-09-21
TN2015000348A1 (en)	2017-01-03
IL272042A (en)	2020-02-27
AP2015008708A0 (en)	2015-09-30
SI2964258T1 (sl)	2020-10-30
US20150232552A1 (en)	2015-08-20
TW201520225A (zh)	2015-06-01
BR112015019611B1 (pt)	2023-05-02
ZA201505285B (en)	2017-11-29
UA123198C2 (uk)	2021-03-03
NL301247I1 (nl)	2023-10-11
HK1212252A1 (en)	2016-06-10
HUS2300036I1 (hu)	2024-07-28
IL272042B (en)	2021-07-29
US9688753B2 (en)	2017-06-27
DK2964258T3 (da)	2020-09-14
LTPA2023530I1 (fr)	2023-11-10
KR20150113202A (ko)	2015-10-07
IL240731B (en)	2020-01-30
CN105307681A (zh)	2016-02-03
NO2023037I1 (no)	2023-10-04
SG11201507176VA (en)	2015-10-29
AU2014226094A1 (en)	2015-08-27
JP2016510744A (ja)	2016-04-11
RS60928B1 (sr)	2020-11-30
CA2901462C (fr)	2017-07-25
NL301247I2 (nl)	2023-11-01
WO2014137962A1 (fr)	2014-09-12
CY1123589T1 (el)	2022-03-24
CY2023021I2 (el)	2024-09-20
LT2964258T (lt)	2020-10-12
IL240731A0 (en)	2015-10-29
EP4311558A2 (fr)	2024-01-31
AR094877A1 (es)	2015-09-02
HUE051357T2 (hu)	2021-03-01
US20140255422A1 (en)	2014-09-11
MX370396B (es)	2019-12-11
FIC20230030I1 (fi)	2023-10-03
FR23C1036I2 (fr)	2024-10-04
EP3789037A1 (fr)	2021-03-10
LTC2964258I2 (fr)	2025-09-10
MX2015011959A (es)	2016-04-07
CY2023021I1 (el)	2024-02-16
KR101775115B1 (ko)	2017-09-05
US9023358B2 (en)	2015-05-05
EP2964258B1 (fr)	2020-09-02
CN105307681B (zh)	2018-06-26
ECSP15038626A (es)	2015-11-30
EP2964258A4 (fr)	2016-10-12
US20170275356A1 (en)	2017-09-28
EA201591368A1 (ru)	2015-12-30
AU2014226094C1 (en)	2024-10-24
PL2964258T3 (pl)	2021-02-08
BR112015019611A2 (pt)	2017-08-22
MY171226A (en)	2019-10-03
NZ711147A (en)	2021-03-26
EA031524B1 (ru)	2019-01-31
CA2901462A1 (fr)	2014-09-12
JOP20140049B1 (ar)	2021-08-17
PT2964258T (pt)	2020-11-06
CL2015002388A1 (es)	2016-03-04
ES2822662T3 (es)	2021-05-04
EP2964258A1 (fr)	2016-01-13
KR20170103037A (ko)	2017-09-12

Publication	Publication Date	Title
FR23C1036I2 (fr)	2024-10-04	Anticorps qui se lient à il-23
FR25C1038I1 (fr)	2025-11-21	Conjugue anticorps anti-trop2-medicament
DK3049441T3 (da)	2020-02-03	Anti-PDL1-antistofformuleringer
DK3736291T5 (da)	2024-08-26	Anti-FCRH5-antistoffer
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
IL267382A (en)	2019-08-29	Oncostatin m receptor antigen binding proteins
EP2970505A4 (fr)	2016-10-19	Anticorps bispécifiques et leurs utilisations
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
ME03675B (fr)	2020-10-20	Anticorps anti-cd3 humanisés ou chimères
HUE051496T2 (hu)	2021-03-01	TL1A-hoz specifikusan kötõdõ ellenanyagok
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
EP2968553A4 (fr)	2016-10-19	Formulations d'anticorps
EP2981286A4 (fr)	2016-08-24	Anticorps anti-il-4 et anticorps bispécifiques et leurs utilisations
FR3014362B1 (fr)	2017-03-17	Ensemble roulant perfectionne
DK3068800T3 (da)	2019-10-21	FcRn-specifikke antistoffer
EP2948981A4 (fr)	2016-03-23	Ensemble thermoélectrique
MA42843A (fr)	2018-07-25	Anticorps anti-cd115
EP3381941A4 (fr)	2019-05-01	Anticorps anti-epha4
EP3336185A4 (fr)	2019-01-16	Anticorps
EP3336184A4 (fr)	2019-01-23	Anticorps
DK3065774T3 (da)	2021-08-23	Anti-CCL17-antistoffer
EP2830663A4 (fr)	2016-07-27	Anticorps complètement humains qui se lient à vegfr2
EP2970503A4 (fr)	2016-11-30	Anticorps monoclonaux anti-(+)-méthamphétamine
FR3002228B1 (fr)	2016-02-19	Anticorps monoclonal et utilisations